Roche to Halt Lung Cancer Trial After Results Miss Goals
By Adria Calatayud
Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after it failed to meet the trial's primary efficacy goals.
The Swiss pharmaceutical company said Thursday that its investigational tiragolumab drug in combination with its cancer immunotherapy Tecentriq and chemotherapy didn't meet the trial's objectives of progression-free survival and overall survival at its first interim analysis. Tiragolumab is thought to act as an amplifier of the body's immune response to cancer with other cancer drugs, it added.
The drug combination showed reduced efficacy compared to the comparator arm, Roche said. The trial compared tiragolumab, Tecentriq and chemotherapy against Merck's Keytruda and chemotherapy.
"These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer," Roche Chief Medical Officer and Head of Global Product Development Levi Garraway said.
Safety data were consistent with previous studies, the company said.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
July 04, 2024 01:35 ET (05:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations